Inhaling vitamin D may boost lung health for millions of people living with chronic respiratory conditions, researchers have said, as evidence mounts that traditional oral supplements fail to reach the airways where they are most needed.
The potential benefits are wide-ranging. Direct delivery of the vitamin to the lungs via inhalation could reduce harmful inflammation, strengthen the lungs’ natural immune defences, support airway repair and lessen the frequency or severity of flare-ups – the acute worsening of symptoms that often sends patients to hospital. Animal studies have already shown that inhaled vitamin D can protect against dust, pollution and pathogens, while cell and animal models suggest that aerosolised vitamin D can reduce ozone-induced inflammation and oxidative stress.
The problem, however, is that millions of people with lung diseases – including chronic obstructive pulmonary disease (COPD), cystic fibrosis and asthma – have low levels of vitamin D, and this is strongly linked to worse outcomes such as more frequent infections, poorer lung function and higher hospitalisation rates. Yet oral vitamin D supplements, widely taken but not federally approved for treatment, have consistently failed to deliver significant clinical benefits in trials. The COPD Foundation said recent research shows that simply raising vitamin D levels in the blood is not enough to improve lung health.
Why oral vitamin D fails the lungs
The explanation lies in what happens after a tablet is swallowed. Once taken by mouth, vitamin D travels to the liver and is processed before spreading through the bloodstream. En route to the lungs, researchers believe it hits a critical snag. Kevin Schichlein, a researcher at the University of North Carolina at Chapel Hill, explained: “Oral vitamin D is potentially inactivated by an enzyme in the lung’s blood vessels, preventing it from reaching the airways.” This inactivation means that even if blood levels are raised, the vitamin never arrives in sufficient concentration at the airway tissue where it is needed. Although the respiratory epithelium has the biological machinery to metabolise vitamin D locally – including enzymes necessary for local calcitriol synthesis – oral delivery cannot take advantage of this because the active compound is blocked before it arrives.
There is a partial exception. A study from Queen Mary University of London found that oral vitamin D supplements reduced COPD flare-ups by more than 40% in patients who had a severe deficiency. But for the majority of patients whose levels are not profoundly low, oral supplementation has shown limited benefit. The paradox – that low vitamin D is strongly associated with poor respiratory health yet oral supplements do not work – has driven researchers to look for an alternative route.
Inhaled delivery: a targeted approach
Inhaling vitamin D directly into the lungs could bypass the inactivation process entirely. The approach treats the lung as a local target, potentially reducing the amount of vitamin D circulating in the rest of the body and minimising systemic side effects. If proven effective, it could also be a low-cost add-on therapy for the more than 35 million Americans who suffer from lung diseases such as COPD, cystic fibrosis and asthma, according to the American Lung Association.
Ilona Jaspers, a professor in paediatrics at the UNC School of Medicine, noted that the concept is not entirely new. “Topical or inhaled delivery of vitamin D is already being explored for upper airway diseases with data from preclinical models and some preliminary clinical trials showing promising results,” she said. “Moving to the lower airways could be a logical extension of these observations.” Human clinical trials are now needed to determine safety, optimal dosage and efficacy, and researchers are also investigating novel drug delivery systems such as nanoparticles to target the lungs more precisely.
Reducing inflammation is a central goal. While inflammation is the body’s normal defence against viruses and bacteria, in major lung conditions it becomes harmful – triggering genetic mutations, damaging lung tissue and blocking the flow of air. By delivering vitamin D directly to the site of inflammation, inhaled therapy could address this damage at its source.
The link between low vitamin D and specific lung diseases is well documented. In asthma, low levels correlate with increased exacerbation rates, reduced lung function and poor symptom control. Among patients with cystic fibrosis, near-universal vitamin D deficiency due to malabsorption is common, and the Cystic Fibrosis Foundation recommends that all individuals with the condition maintain serum 25-hydroxyvitamin D levels of at least 30 ng/ml (75 nmol/litre). In interstitial lung disease, a study found that individuals with vitamin D deficiency had larger areas of lung tissue damage and were more likely to have early signs of the disease compared with those who had recommended levels.
Inflammation can trigger genetic mutations, damage lung tissue and block your flow of air.
